These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2433967)

  • 21. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
    Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Torsade de pointes induced by N-acetylprocainamide.
    Chow MJ; Piergies AA; Bowsher DJ; Murphy JJ; Kushner W; Ruo TI; Asada A; Talano JV; Atkinson AJ
    J Am Coll Cardiol; 1984 Sep; 4(3):621-4. PubMed ID: 6206104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inotropic actions of N-acetylprocainamide: blockade and reversal by propranolol.
    Lertora JJ; King LW; Donkor KA
    Angiology; 1986 Dec; 37(12 Pt 2):939-49. PubMed ID: 2433968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
    Anderson JL
    Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electropharmacodynamics of N-acetylprocainamide in the immature mammalian heart--evidence for a prominent class III effect in the newborn.
    Dise T; Stolfi A; Yamasaki S; Pickoff AS
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):96-101. PubMed ID: 1708063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of evoked endocardial response for assessment of antiarrhythmic drug effects on myocardium.
    Furukawa T; Taniguchi K; Takeuchi J
    Bull Tokyo Med Dent Univ; 1988 Sep; 35(3):33-44. PubMed ID: 2466578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
    Robertson DW; Beedle EE; Wilson H; Parli CJ; Smallwood JK; Steinberg MI
    J Med Chem; 1988 Jul; 31(7):1290-5. PubMed ID: 3385724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of procainamide and N-acetylprocainamide on atrial flutter: studies in vivo and in vitro.
    Wu KM; Hoffman BF
    Circulation; 1987 Dec; 76(6):1397-408. PubMed ID: 2445503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrophysiologic effects of N-acetylprocainamide in human beings.
    Jaillon P; Rubenson D; Peters F; Mason JW; Winkle RA
    Am J Cardiol; 1981 May; 47(5):1134-40. PubMed ID: 6164285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias.
    Singh BN
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S75-90. PubMed ID: 1279313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide.
    Winkle RA; Jaillon P; Kates RE; Peters F
    Am J Cardiol; 1981 Jan; 47(1):123-30. PubMed ID: 6161534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol.
    Fiset C; Drolet B; Hamelin BA; Turgeon J
    J Pharmacol Exp Ther; 1997 Oct; 283(1):148-56. PubMed ID: 9336319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias.
    Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ
    Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of procainamide and its N-acetylated metabolite in conscious dogs with atrioventricular block: plasma concentration-response relationships.
    Boucher M; Dubray C; Paire M; Duchêne-Marullaz P
    J Cardiovasc Pharmacol; 1987 Nov; 10(5):562-7. PubMed ID: 2447406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basic cardiac electrophysiology and mechanisms of antiarrhythmic agents.
    Perry RS; Illsley SS
    Am J Hosp Pharm; 1986 Apr; 43(4):957-74. PubMed ID: 2871752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.
    Lee WK; Strong JM; Kehoe RF; Dutcher JS; Atkinson AJ
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):508-14. PubMed ID: 776488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amiodarone as paradigm for developing new drugs for atrial fibrillation.
    Singh BN
    J Cardiovasc Pharmacol; 2008 Oct; 52(4):300-5. PubMed ID: 18841075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
    Giardina EG
    Ann N Y Acad Sci; 1984; 432():177-88. PubMed ID: 6084435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias.
    Kluger J; Drayer D; Reidenberg M; Ellis G; Lloyd V; Tyberg T; Hayes J
    Am J Cardiol; 1980 Jun; 45(6):1250-7. PubMed ID: 6155064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.